KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
LONDON
Loading...
Price History
Market Data
| Market Cap | - |
| P/E Ratio | - |
| P/B Ratio | - |
| EPS | 0.45 |
| Dividend Yield | - |
| D/E Ratio | 0.33 |
| Current Ratio | 3.85 |
| Currency | USD |
Key Financial Metrics
597.97M
Revenue
35.92M
Net Income
0.45
EPS (Diluted)
174.11M
Free Cash Flow
Profitability
Gross Margin
87.5%
Operating Margin
6.4%
Net Profit Margin
6.0%
EBITDA
40.69M
Returns & Efficiency
Return on Assets (ROA)
5.0%
Return on Equity (ROE)
6.7%
Dividend Yield
-
EPS
0.45
Financial Health
Total Assets
712.33M
Total Debt
-
Debt to Equity
0.33x
Current Ratio
3.85
Insider Trading
Last 12 months
0
Buys
0
Sells
0
Insiders
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Company Info
| HQ | LONDON |
| Fiscal Year | 2024 |
Peers
LILLY ELI & CO
LLY
954.09B
P/E: --
ELI LILLY & CO
LLY
954.09B
P/E: --
530.38B
P/E: --
ABBVIE INC.
ABBV
387.52B
P/E: --
270.21B
P/E: --
MERCK & CO. INC.
MRK
270.21B
P/E: --
270.21B
P/E: --
186.96B
P/E: --
Quick Links
Financial Statistics
Valuation
Market Cap-
P/E Ratio (TTM)-
Price to Book-
EV/Revenue-
EV/EBITDA-
Profitability
Gross Margin87.5%
Operating Margin6.4%
Net Margin6.0%
ROE6.7%
ROA5.0%
Leverage & Liquidity
Debt to Equity0.33
Current Ratio3.85
Total Debt-
Total Assets$712.33M
Stockholders' Equity$535.38M
Income Statement (FY 2024)
Revenue$597.97M
Gross Profit$523.35M
Operating Income$38.15M
Net Income$35.92M
EPS (Diluted)$0.45
Cash Flow (FY 2024)
Free Cash Flow$174.11M
Cash & Equivalents$174.86M
Revenue Growth-
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address | 23 OLD BOND STREET, FLOOR 3 LONDON, None WIS 4PZ |
| Phone | 7814319100 |
| Incorporated | None, GB |
| EIN | 000000000 |
| Fiscal Year End | 1231 |
| Shares Outstanding | 74.71M |
| Stockholders' Equity | $535.38M |
| Cash & Equivalents | $174.86M |
Recent Filings
View All
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-11
Local
144
Proposed Sale Notice
Notice of proposed sale of securities
Filed: 2026-03-09
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-04
Local
144
Proposed Sale Notice
Notice of proposed sale of securities
Filed: 2026-03-02
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-02-24
Local
S-8
Employee Plan Registration
Registration for employee benefit plan securities
Filed: 2026-02-24
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2026-02-24
Local
SCHEDULE 13G/A
Amended Schedule 13G
Amendment to Schedule 13G
Filed: 2026-02-13
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-02-12
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-02-11
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-10-28
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-07-29
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-04-29
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2025-04-21
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2025-02-25
Local
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Company Profile
General Information
| Company Name | KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC |
| Ticker | KNSA |
| Exchange | -- |
| Sector | Manufacturing |
| Industry | -- |
| Headquarters | LONDON |
| Fiscal Year | 2024 |
Financial Summary
| Market Cap | - |
| Revenue | 597.97M |
| Net Income | 35.92M |
| P/E Ratio | - |
| EPS | 0.45 |
| Net Margin | 6.0% |
| ROE | 6.7% |
| Dividend Yield | - |
Insider Transactions
Loading...
My Notes & Files
Personal Notes
Attached Files
Loading...